JNJ: Dividend King with a Pharma Growth Engine

The Numbers at a Glance

• Price: ~$229.58
• Market cap: ~$553.8B
• P/E (TTM): 26.5x
• Dividend yield: 2.36% ($5.36/share annually)
• Consecutive dividend increases: 54 years — Dividend King status
• Analyst consensus: Buy | Avg price target ~$249–$258 (8–12% upside)
• 2026 revenue guidance: $100.8B

Q1 2026: Quiet Beat, No Drama

Johnson & Johnson reported Q1 2026 revenue of $24.1 billion, up 10% year-over-year, beating the Wall Street consensus of $23.6B. Adjusted EPS came in at $2.70, ahead of the $2.68 estimate — the fourth consecutive quarter of consensus beats.

The breakdown tells the real story:

• Innovative Medicine: +11.2% — the pharma engine is running
• MedTech: +7.7% — surgical systems, orthopedics, and vision recovering steadily

Full-year 2026 guidance was raised to $100.8B in revenue — J&J is on track to cross the $100B threshold for the first time. That's not a small milestone for a company that existed before the Federal Reserve did.

The Pipeline: What's Carrying the Load

The narrative on J&J for the past two years has been centered on one word: Stelara. The blockbuster immunology drug lost exclusivity and biosimilar competition hit hard — a 1,040 basis point headwind in 2025. The market spent two years pricing in that cliff.

What the market underestimated was how fast the pipeline was building behind it:

• Darzalex: $14.4 billion in 2025 sales, patent protected to approximately 2029. The multiple myeloma standard of care globally. Still growing double digits.
• Tremfya: $5.2 billion in 2025, up 40.5% year-over-year. Immunology competitor to AbbVie's Skyrizi, with expanding indications across psoriasis and IBD.
• Spravato: Treatment-resistant depression. Unique mechanism, real clinical differentiation, and growing rapidly in an underpenetrated market.
• Carvykti: CAR-T therapy for multiple myeloma. Limited availability right now but manufacturing is scaling — this becomes a multi-billion franchise over the next 3 years.
• Erleada: Prostate cancer. Steady grower with protected patent life into the late 2020s.

The Stelara headwind is absorbed. Darzalex and Tremfya alone represent more than enough runway to sustain the Innovative Medicine segment through the end of this decade, and the next patent cliff (Darzalex ~2029) is far enough out that J&J has time to build the layer after this one.

The Talc Overhang

There's no clean way to discuss J&J without acknowledging the talc litigation. As of Q4 2025, the company faces 74,360 active lawsuits alleging that it knowingly sold talcum powder containing asbestos. The company's attempt to use a Texas subsidiary bankruptcy (Red River Talc) to consolidate and settle these claims was rejected by the court, allowing individual cases to proceed.

This matters. It creates ongoing legal costs — $0.3 billion in charges in Q1 2026 alone — and unpredictable headline risk. Any unfavorable jury verdict in a high-profile case can move the stock 3–5% in a session.

The thesis here isn't that the talc liability is small. It's that the business generates enough cash ($19+ billion annually) to absorb even a significant settlement, and the legal overhang has been priced in for years. Every person who's waited for "resolution" has missed the compounding. At some point — likely in the next 2–3 years — J&J reaches a global settlement and this becomes a footnote.

Dividend King: 54 Years, No Cuts

Johnson & Johnson has raised its dividend every single year since 1972. It survived the 1987 crash, the dot-com bust, the 2008 financial crisis, COVID, and Stelara's cliff — all without cutting the dividend once.

The current yield is 2.36%, with the next ex-dividend date on May 26, 2026. That's not a yield that will make income investors swoon, but for a stock that's compounded at 10%+ total return for decades, it's the floor, not the ceiling.

For investors who hold through a full market cycle, the dividend reinvestment math on JNJ is powerful. Every pullback is a higher-yield entry point on what has proven to be one of the most durable cash machines in US equities.

Valuation

At 26.5x earnings, JNJ doesn't scream cheap. But it's within its historical range, and the earnings quality here is high — these aren't GAAP distortions, and the revenue is recurring, diversified across 150+ countries, and not dependent on a single product cycle.

The analyst consensus price target of $249–$258 implies 8–12% upside from current levels. Add in the 2.36% dividend and you're looking at a 10–14% total return thesis on one of the most defensive names on the planet.

For comparison: at 26.5x, JNJ is cheaper than the S&P 500 median, pays more yield, and has less earnings volatility than most "defensive" names.

The Risks — Honest Version

• Talc liability uncertainty: The legal path is long, and individual verdicts are unpredictable. A $10B+ settlement isn't off the table.
• Patent cliffs 2029–2031: Darzalex loses exclusivity around 2029. This is the next Stelara moment, and J&J will need to repeat what it's doing now — except from a more mature pipeline base.
• MedTech competitive pressure: Robotic surgery (Medtronic, Intuitive) is intensifying. J&J's Ottava platform is behind schedule and needs to prove itself.
• Drug pricing risk: IRA drug pricing negotiation is an ongoing headwind across the industry. J&J is not immune.

My Thesis

JNJ at $229 is the kind of stock that doesn't need a catalyst — it just needs time. The business is compounding quietly. The Stelara cliff is in the rearview. Darzalex and Tremfya are both growing double digits with years of protected runway ahead. The dividend streak is 54 years strong and the payout ratio gives room for further increases.

The talc litigation is real but it's been in the price for years. The next patent cliff isn't until 2029 — that's a long runway for a company that generates $19+ billion in annual free cash flow to build the next layer.

This isn't a LEAP play. JNJ doesn't move fast. But for a portfolio that needs a quality anchor — something that holds during the disorderly BOJ unwind scenario, the Fed miscalculation, or the next macro panic — this is the kind of name that lets you sleep. You're not buying JNJ for the upside. You're buying it because it's the base that lets you take risk elsewhere.

Watchlist entry at current levels. Accumulate on any pullback below $215.